That is the title of my guest column at The Evidence Base. An excerpt is below:
Multiple indicators suggest that health economics and outcomes research (HEOR) faces unprecedented challenges to its traditional role in pharmaceutical value demonstration. Yet these apparent threats may signal evolution rather than decline – if the field can adapt to serve broader stakeholder needs beyond traditional payers. In this Guest Column, Jason Shafrin asks: has HEOR truly reached its peak, or is it evolving to meet the complex demands of modern healthcare decision-making?
You can read the full column here.
